Jul, 2023

U.S.A.
News / Therapeutic Area News
Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application
If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal cancers TOKYO, July 6, 2023 /PRNewswire/ -- Astellas Pharma Inc....
Read More

Jun, 2023

U.S.A.
News / Therapeutic Area News
Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause
Study evaluated 24-week efficacy and safety of Astellas' fezolinetant in women considered unsuitable for hormone therapy TOKYO, June 27, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503,...
Read More
U.S.A.
News / Therapeutic Area News
Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD Acute Myeloid Leukemia Patients
Data from Phase 3 MORPHO trial selected for press briefing and to be presented as oral session during the 2023 European Hematology Association (EHA) Hybrid Congress Exploratory results...
Read More
U.S.A.
News / Therapeutic Area News
Astellas Submits New Drug Application for Zolbetuximab in Japan
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers TOKYO, June 9, 2023 /PRNewswire/ -- Astellas...
Read More
U.S.A.
News / Therapeutic Area News
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
KT430 is a preclinical, next-generation investigational gene therapy to treat X-linked myotubular myopathy (XLMTM) TOKYO and SAN DIEGO, June 8, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE:...
Read More